ImmunoCellular Therapeutics (NASDAQ:IMUC) released its earnings data on Monday. The company reported ($0.04) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.06) by $0.02, American Banking News.com reports.
A number of research firms have recently commented on IMUC. Analysts at Roth Capital upgraded shares of ImmunoCellular Therapeutics from a “neutral” rating to a “buy” rating in a research note on Monday, June 2nd. They now have a $3.00 price target on the stock, up previously from $2.00. Analysts at Maxim Group cut their price target on shares of ImmunoCellular Therapeutics from $12.00 to $4.00 in a research note on Monday, June 2nd. They now have a “buy” rating on the stock. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $3.31.
ImmunoCellular Therapeutics (NASDAQ:IMUC) opened at 0.9159 on Monday. ImmunoCellular Therapeutics has a 52-week low of $0.65 and a 52-week high of $4.00. The stock’s 50-day moving average is $1.03 and its 200-day moving average is $1.19. The company’s market cap is $53.1 million.
ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is engaged in developing immune-based therapies for the treatment of cancers, such as brain, ovarian and other solid tumors.
Stay on top of analysts' coverage of ImmunoCellular Therapeutics Ltd with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.